Related Experiment Video
Updated: Dec 19, 2025
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Emerging Roles of Dysregulated MicroRNAs in Myasthenia Gravis
1Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Abstract:
Myasthenia gravis (MG) is a rare acquired autoimmune neuromuscular disease. Autoantibodies, cellular immunity, complement, and cytokines are involved in the pathogenesis of MG. It is characterized by the dysfunction of neuromuscular junction transmission and skeletal muscle weakness. MicroRNAs (miRNAs) are non-coding small molecule ribonucleic acids that regulate various biological processes (e.g., development, differentiation, and immunity) at the transcriptional and post-transcriptional levels of gene expression. miRNAs play an important regulatory role in the pathogenesis of autoimmune diseases, including MG. In recent studies, the functional mechanisms underlying the role of miRNAs in the pathogenesis of MG have received increasing attention. miRNAs are highly stable and have high specificity in peripheral body fluids. Therefore, the miRNAs in body fluids may represent promising biomarkers for determining the prognosis of MG and the efficacy of treatment. This article reviews the role of miRNAs in the pathogenesis of MG, highlights the potential of miRNAs as new biomarkers for the diagnosis of MG, and deepens our understanding of disease processes.
Insights
MicroRNAs (miRNAs) are key regulators in myasthenia gravis (MG) pathogenesis. Their stability and specificity in body fluids suggest potential as diagnostic and prognostic biomarkers for this autoimmune neuromuscular disease.
Area of Science:
- Immunology
- Neurology
- Molecular Biology
Background:
- Myasthenia gravis (MG) is a rare autoimmune neuromuscular disorder affecting neuromuscular junction transmission, leading to skeletal muscle weakness.
- The pathogenesis of MG involves autoantibodies, cellular immunity, complement, and cytokines.
- MicroRNAs (miRNAs), small non-coding RNAs, regulate gene expression and are implicated in autoimmune disease development.
Purpose of the Study:
- To review the role of miRNAs in the pathogenesis of myasthenia gravis.
- To highlight the potential of miRNAs as novel biomarkers for MG diagnosis.
- To deepen the understanding of disease mechanisms in MG.
Main Methods:
- Review of recent scientific literature focusing on miRNA function in MG.
- Analysis of studies investigating miRNA regulatory roles in autoimmune processes.
- Evaluation of miRNA stability and specificity in peripheral body fluids.
Main Results:
- MicroRNAs play a significant regulatory role in the pathogenesis of myasthenia gravis.
- MiRNAs are implicated in the molecular mechanisms underlying MG.
- MiRNAs exhibit high stability and specificity in peripheral body fluids.
Conclusions:
- MiRNAs are crucial in the development and progression of myasthenia gravis.
- Circulating miRNAs show promise as potential biomarkers for MG diagnosis and prognosis.
- Further research into miRNAs can enhance understanding and treatment strategies for MG.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:21Satellite Stem Cells and Muscular Dystrophy